News
MSD says subcutaneous Keytruda matches IV form

MSD says subcutaneous Keytruda matches IV form

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.

News
Zhiyong Lu, senior investigator NIH/NLM

NIH algorithm matches patients to clinical trials

Researchers from the National Institutes of Health (NIH) are applying artificial intelligence to the recruitment of volunteers into clinical trials, aiming to solve a major obstacle in clin

Sales & Marketing

Digital

News
Zhiyong Lu, senior investigator NIH/NLM

NIH algorithm matches patients to clinical trials

Researchers from the National Institutes of Health (NIH) are applying artificial intelligence to the recruitment of volunteers into clinical trials, aiming to solve a major obstacle in clin

Market Access

Editor's Picks

  1. Trump pick of RFK for top US health job astounds critics News
  2. 23andMe ends drug development and slashes staff
  3. BioNTech buys Biotheus and its Keytruda rival for $950m
  4. Chasing $80bn sales target, AZ unveils $3.5bn US investment News
  5. London "is number one European city in life sciences"

Newsletters and Deep Dive
digital magazine

Oncology

News
MSD says subcutaneous Keytruda matches IV form

MSD says subcutaneous Keytruda matches IV form

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.

Patients

R&D

News
MSD says subcutaneous Keytruda matches IV form

MSD says subcutaneous Keytruda matches IV form

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.

News
Zhiyong Lu, senior investigator NIH/NLM

NIH algorithm matches patients to clinical trials

Researchers from the National Institutes of Health (NIH) are applying artificial intelligence to the recruitment of volunteers into clinical trials, aiming to solve a major obstacle in clin

Partner Content

Patients
Patient Recruitment for Rare Disease Trials Summit banner image
Partner Content

Patient Recruitment for Rare Disease Trials Summit

Recruiting patients for rare disease trials is akin to finding a needle in a haystack, with challenges such as geographical dispersion, low awareness, and limited eligible patient pools.